Evaluation of potential modifiers of the cardiac phenotype in the 22q11.2 deletion syndrome

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 85, Issue 2, 2009, Pages 125-129

  Goldmuntz, Elizabeth ^a   Driscoll, Deborah A ^b,d   Emanuel, Beverly S ^a   McDonald McGinn, Donna ^a   Mei, Minghua ^c   Zackai, Elaine ^a   Mitchell, Laura E ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Birth defect; Congenital heart disease; Conotruncal defect; Folate; Genetic

Indexed keywords

DNA; FOLIC ACID; HOMOCYSTEINE;

22Q11 2 DELETION SYNDROME; AORTA ARCH ANOMALY; ARTICLE; BIRTH DEFECT; CHROMOSOME DELETION; CONGENITAL HEART MALFORMATION; DISEASE ASSOCIATION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETERODUPLEX ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RACE; RISK ASSESSMENT; SEX DIFFERENCE;

CHILD; CONTINENTAL POPULATION GROUPS; DIGEORGE SYNDROME; FEMALE; GENE FREQUENCY; GENOTYPE; HEART DEFECTS, CONGENITAL; HUMANS; INDIVIDUALITY; MALE; PHENOTYPE; PREVALENCE; RISK FACTORS; SEX FACTORS;

EID: 62949201535     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20501     Document Type: Article

References (32)

1. Barbaux S, Kluijtmans LA, Whitehead AS. 2000. Accurate and rapid "multiplex heteroduplexing" method for genotyping key enzymes involved in folate/homocysteine metabolism. Clin Chem 46:907-912.
2. Botto LD, Khoury MJ, Mulinare J, et al. 1996. Periconceptional multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case-control study. Pediatrics 98:911-917.
3. Botto LD, Mastroiacovo P. 1998. Exploring gene-gene interactions in the etiology of neural tube defects. Clin Genet 53:456-459.
4. Botto LD, May K, Fernhoff PM, et al. 2003. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112:101-107.
5. Botto LD, Mulinare J, Erickson JD. 2000. Occurrence of congenital heart defects in relation to maternal multivitamin use. Am J Epidemiol 151:878-884.
6. Carlson C, Sirotkin H, Pandita R, et al. 1997. Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients. Am J Hum Genet 61:620-629.
7. Christensen B, Arbour L, Tran P, et al. 1999. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 84:151-157.
8. Czeizel AE. 1996. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. Am J Med Genet 62:179-183.
9. Czeizel AE, Dudas I. 1992. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327:1832-1835.
10. Desmaze C, Prieur M, Amblard F, et al. 1993. Physical mapping by FISH of the DiGeorge critical region (DGCR): involvement of the region in familial cases. Am J Hum Genet 53:1239-1249.
11. Driscoll DA, Boland T, Emanuel BS, et al. 2006. Evaluation of potential modifiers of the palatal phenotype in the 22q11.2 deletion syndrome. Cleft Palate Craniofac J 43:435-441.
12. Driscoll DA, Salvin J, Sellinger B, et al. 1993. Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes: implications for genetic counselling and prenatal diagnosis. J Med Genet 30:813-817.
13. Frosst P, Blom HJ, Milos R, et al. 1995. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113.
14. Goldmuntz E. 2005. DiGeorge syndrome: new insights. Clin Perinatol 32:963-978, ix-x.
15. Goldmuntz E, Clark BJ, Mitchell LE, et al. 1998. Frequency of 22q11 deletions in patients with conotruncal defects. J Am Coll Cardiol 32:492-498.
16. Jenkins KJ, Correa A, Feinstein JA, et al. 2007. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 115:2995-3014.
17. Junker R, Kotthoff S, Vielhaber H, et al. 2001. Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease. Cardiovasc Res 51:251-254.
18. Lambrechts D, Devriendt K, Driscoll DA, et al. 2005. Low expression VEGF haplotype increases the risk for tetralogy of Fallot: a family based association study. J Med Genet 42:519-522.
19. Leclerc D, Campeau E, Goyette P, et al. 1996. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 5:1867-1874.
20. McDonald-McGinn DM, LaRossa D, Goldmuntz E, et al. 1997. The 22q11.2 deletion: screening, diagnostic workup, and outcome of results; report on 181 patients. Genet Test 1:99-108.
21. Morrow B, Goldberg R, Carlson C, et al. 1995. Molecular definition of the 22q11 deletions in velo-cardio-facial syndrome. Am J Hum Genet 56:1391-1403.
22. MRC. 1991. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 338:131-137.
23. Perry LW, Neill CA, Ferencz C, et al. 1993. Infants with congenital heart disease: the cases. In: Ferencz C, Rubin JD, Loffredo CA, et al., editors. Epidemiology of Congenital Heart Disease: The Baltimore-Washington Infant Study 1981-1989. Mount Kisco: Futura Publishing Company, Inc. p 33-62.
24. Ryan AK, Goodship JA, Wilson DI, et al. 1997. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet 34:798-804.
25. Saitta SC, Harris SE, Gaeth AP, et al. 2004. Aberrant interchromosomal exchanges are the predominant cause of the 22q11.2 deletion. Hum Mol Genet 13:417-428.
26. Scambler PJ, Carey AH, Wyse RK, et al. 1991. Microdeletions within 22q11 associated with sporadic and familial DiGeorge syndrome. Genomics 10:201-206.
27. Sebastio G, Sperandeo MP, Panico M, et al. 1995. The molecular basis of homocystinuria due to cystathionine beta-synthase deficiency in Italian families, and report of four novel mutations. Am J Hum Genet 56:1324-1333.
28. Stalmans I, Lambrechts D, De Smet F, et al. 2003. VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat Med 9:173-182.
29. van der Put NM, Steegers-Theunissen RP, Frosst P, et al. 1995. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 346:1070-1071.
30. Wenstrom KD, Johanning GL, Johnston KE, et al. 2001. Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations. Am J Obstet Gynecol 184:806-812.
31. Whitehead AS, Gallagher P, Mills JL, et al. 1995. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. QJM 88:763-766.
32. Wilson A, Platt R, Wu Q, et al. 1999. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 67:317-323.